| Anti-PD1 antibodies and their use as therapeutics and diagnostics K Li, T Zhang, J Song, L Xu, Q Liu, H Peng US Patent 8,735,553, 2014 | 278 | 2014 |
| The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions T Zhang, X Song, L Xu, J Ma, Y Zhang, W Gong, Y Zhang, X Zhou, ... Cancer Immunology, Immunotherapy 67, 1079-1090, 2018 | 262 | 2018 |
| Chimeric NK-receptor–bearing T cells mediate antitumor immunotherapy T Zhang, BA Lemoi, CL Sentman Blood 106 (5), 1544-1551, 2005 | 199 | 2005 |
| Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor T Zhang, A Barber, CL Sentman Cancer research 66 (11), 5927-5933, 2006 | 185 | 2006 |
| FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy X Chen, xiaomin Song, K Li, T Zhang Frontiers in Immunology 10, 2019 | 143 | 2019 |
| Anti-PD1 antibodies and their use as therapeutics and diagnostics K Li, T Zhang, J Song, L Xu, Q Liu, H Peng US Patent 9,217,034, 2015 | 141 | 2015 |
| An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo T Zhang, MR Wu, CL Sentman The Journal of Immunology 189 (5), 2290-2299, 2012 | 141 | 2012 |
| Chimeric NKG2D receptor–bearing T cells as immunotherapy for ovarian cancer A Barber, T Zhang, LR DeMars, J Conejo-Garcia, KF Roby, CL Sentman Cancer research 67 (10), 5003-5008, 2007 | 126 | 2007 |
| Chimeric NK receptor and methods for treating cancer T Zhang, CL Sentman US Patent 7,994,298, 2011 | 116 | 2011 |
| Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer A Barber, T Zhang, CL Sentman The Journal of Immunology 180 (1), 72-78, 2008 | 105 | 2008 |
| Chimeric NKG2D receptor–expressing T cells as an immunotherapy for multiple myeloma A Barber, T Zhang, CJ Megli, J Wu, KR Meehan, CL Sentman Experimental hematology 36 (10), 1318-1328, 2008 | 101 | 2008 |
| Chimeric NKG2D–modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways T Zhang, A Barber, CL Sentman Cancer research 67 (22), 11029-11036, 2007 | 101 | 2007 |
| Chimeric NK receptor and methods for treating cancer T Zhang, CL Sentman US Patent 8,252,914, 2012 | 99 | 2012 |
| Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells T Zhang, CL Sentman Cancer research 71 (6), 2066-2076, 2011 | 90 | 2011 |
| Transgenic TCR expression: comparison of single chain with full-length receptor constructs for T-cell function T Zhang, X He, TC Tsang, DT Harris Cancer gene therapy 11 (7), 487-496, 2004 | 87 | 2004 |
| NK cell receptors as tools in cancer immunotherapy CL Sentman, MA Barber, A Barber, T Zhang Advances in cancer research 95, 249-292, 2006 | 85 | 2006 |
| B7H6-specific bispecific T cell engagers lead to tumor elimination and host antitumor immunity MR Wu, T Zhang, AT Gacerez, TA Coupet, LR DeMars, CL Sentman The Journal of Immunology 194 (11), 5305-5311, 2015 | 71 | 2015 |
| B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity MR Wu, T Zhang, LR DeMars, CL Sentman Gene therapy 22 (8), 675-684, 2015 | 69 | 2015 |
| Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells T Zhang, CL Sentman The Journal of Immunology 190 (5), 2455-2463, 2013 | 58 | 2013 |
| NK cells rapidly remove B16F10 tumor cells in a perforin and interferon-gamma independent manner in vivo MA Grundy, T Zhang, CL Sentman Cancer Immunology, Immunotherapy 56, 1153-1161, 2007 | 54 | 2007 |
